The ECFS welcomes the approval of Vertex’s KALYDECO (ivacaftor) by the FDA.

Press release available here  [1](external site)

Update from May 25, 2012

Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis.  Further information in the Press Release here [2].